Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2016
Filed with the SEC on Aug 8, 2016 and accepted by EDGAR at Aug 8, 2016, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-04-01 to 2016-06-30 | $1.4m | us-gaap:Revenues |
| Revenue | 6 months2016-01-01 to 2016-06-30 | $2.7m | us-gaap:Revenues |
| Research and development | 3 months2016-04-01 to 2016-06-30 | $25.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-01-01 to 2016-06-30 | $53.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-04-01 to 2016-06-30 | −$32.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-01-01 to 2016-06-30 | −$68.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2016-04-01 to 2016-06-30 | −$32.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2016-01-01 to 2016-06-30 | −$66.6m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2016-04-01 to 2016-06-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2016-01-01 to 2016-06-30 | −$0.67 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 6 months2016-01-01 to 2016-06-30 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-06-30 | $32.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-06-30 | $228.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-06-30 | $271.2m | us-gaap:Assets |
| Current liabilities | At period end2016-06-30 | $20.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-06-30 | $36.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-06-30 | $234.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-16-137913. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.